Texas HB4014 mandates a study on psychedelic therapies for PTSD, depression, and co-occurring conditions.

HB4014 requires the Texas Department of State Health Services to conduct a comprehensive study on the use of psychedelic therapies, including MDMA, psilocybin, and ketamine, for treating post-traumatic stress disorder, depression, and other co-occurring conditions. The study will review clinical trials, current literature, FDA actions, treatment guidelines, and patient access. The department must submit a report by December 1, 2026, with findings and recommendations for ensuring patient access to these therapies post-FDA approval. The act expires on September 1, 2027.

Texas HB4014 mandates a study on psychedelic therapies for PTSD, depression, and co-occurring conditions.

HB4014 requires the Texas Department of State Health Services to conduct a comprehensive study on the use of psychedelic therapies, including MDMA, psilocybin, and ketamine, for treating post-traumatic stress disorder, depression, and other co-occurring conditions. The study will review clinical trials, current literature, FDA actions, treatment guidelines, and patient access. The department must submit a report by December 1, 2026, with findings and recommendations for ensuring patient access to these therapies post-FDA approval. The act expires on September 1, 2027.